Listen and follow our podcasts on:

This educational programme is supported by an Independent Medical Education Grant from Bayer

Listen to the second episode - PSMA-targeted radiopharmaceuticals


Radiopharmaceuticals in prostate cancer - PMSA-targeted pharmaceuticals (Episode 2 of 2)

In this GU CONNECT podcast series international experts, Assoc. Prof. Tanya Dorff and Dr. Phillip Koo, from the field of GU Oncology and Nuclear Medicine, discuss the latest developments in the field of radiopharmaceuticals and their use in prostate cancer.  Episode 2 focuses on PSMA-targeted radiopharmaceuticals.

Episode two focuses on PSMA-targeted radiopharmaceuticals and how PSMA can be a therapeutic target as well as for imaging. Efficacy and safety data from the phase 2 TheraP study are discussed which investigated lutetium-PSMA versus cabazitaxel in patients with mCRPC who had progressed on docetaxel.

The experts also discuss the ongoing VISION trial and what the results may mean for clinical practice as well as other ongoing trials looking at lutetium-PSMA in combination with other prostate cancer therapies such as PARP inhibitors, immunotherapies, hormonal therapies and chemotherapy. Treatment sequencing is also considered in terms of where lutetium-PSMA fits into clinical practice for mCRPC patients and how the treatment compares to Radium-223.

In the first episode, the experts focus on the alpha emitter, radium-223 which received regulatory approval on the basis of the phase 3 ALSYMPCA trial in patients with metastatic castration-resistant prostate cancer (mCRPC) and symptomatic bone metastases. They consider mechanism of action and discuss key results from the trial and the safety profile.

The experts also review the ERA-223 and PEACE-III randomised trials which investigated the use of radium-223 in combination with next-generation androgen receptor inhibitors (ARI’s).  A number of real-world evidence studies are also reviewed as the experts consider where radium-223 fits into the overall treatment sequence for mCRPC patients. Radiation safety and general considerations for delivering therapy with radiopharmaceuticals are also discussed.

Phillip J. Koo, MD is the Division Chief of Diagnostic Imaging at the Banner MD Anderson Cancer Center in Arizona. Prior to this, he was Chief of Nuclear Medicine and Associate Professor of Radiology at the University of Colorado School of Medicine. Dr Koo completed his transitional internship at the University of Pennsylvania Medical Center-Presbyterian, radiology residency at Pennsylvania Hospital of the University of Pennsylvania Health System, and fellowship at the Harvard Medical School Joint Program in Nuclear Medicine. He is a diplomate of both the American Board of Radiology (ABR) and American Board of Nuclear Medicine. Dr Koo is an active member of multiple societies and serves on the Scientific Program Committee for the Radiological Society of North America, Nuclear Radiology Certifying Exam Committee for the ABR, and is the Chair of the Quality and Evidence Committee for the Society of Nuclear Medicine and Molecular Imaging (SNMMI).  He is also Chair of the Prostate Cancer Working Group at the SNMMI and was a member of the RADAR I and II working groups. Dr Koo has published on various topics related to radiology and nuclear medicine in multiple journals such as Radiology, Radiographics, European Journal of Nuclear Medicine and Molecular Imaging, Urology, and Journal of the American College of Radiology.  

Dr Phillip Koo has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

AstraZeneca, Bayer, Blue Earth, Janssen, Lantheus, Merck and Novartis. 

Following a residency at Mt. Sinai Hospital in New York City, Dr Dorff came to LAC + USC Medical Center for her hematology and medical oncology fellowship. She currently heads the Genitourinary group within the Department of Medical Oncology at the City of Hope Comprehensive Cancer Center. In addition to being a devoted clinician and translational researcher, Dr Dorff has authored more than 45 peer reviewed articles as well as 35 review articles/commentaries. Dr Dorff serves as an associate editor for Clinical Genitourinary Cancer and Seminars in Urologic Oncology. She has lectured on prostate and bladder cancer treatment nationally and internationally and has presented her research at national meetings. Current research interests include the effects of fasting on chemotherapy side effects and cancer control and immunotherapy for prostate cancer. She has been the principal investigator for more than a dozen clinical trials, involving targeted therapy and immunotherapy, for genitourinary cancers.

Assoc. Prof. Tanya Dorff has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

AstraZeneca, Astellas, Exelixis, Janssen and SeaGen.

Programme summary
  • clock Duration 22 MIN
  • clock Language(s) flag
Take the e-learning now
Share this programme
This educational programme is supported by an Independent Medical Education Grant from Bayer
Accreditation
EACCME
This course has been accredited by EACCME® for ECMEC®.
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
GU CONNECT

GU CONNECT is an initiative of COR2ED, supported by Independent Educational Medical Grants from Bayer, AstraZeneca and Eisai Europe Limited.

Meet the experts

Other programmes of interest

Breast-Cancer-Connect-ER-HER2-low-thumbnail-BR2310 Tweetorial
Oncology 
Tweetorial video: Treating ER+/HER2-low metastatic breast cancer, 2L and beyond

Journey through a patient case from testing and diagnosis to treatment and AE management

Experts
Dr Aditya Bardia
Endorsed by
GRASP
  • clock 11 MIN
  • calendar Apr 2024

Educational programme supported by an Independent Medical Education grant from Menarini Stemline Oncology.
NSCLC-perseverance-pays-off- thumbnail-PO2305 Podcast
Oncology 
Perseverance in molecular testing in NSCLC pays off

Looking beyond the obvious mutations in non-small-cell lung cancer

Experts
Prof. Frédérique Penault-Llorca, Prof. Mark Socinski
  • download Downloadable
    Resources
  • clock 26 MIN
  • calendar Mar 2024

Educational programme supported by an Independent Medical Education grant from Bayer
Conference update
Oncology 
ER+ advanced breast cancer: Highlights from EBCC-14 satellite symposium

Medical experts discuss current and upcoming treatment strategies to use after CDK4/6 inhibitors in patients with ER+/HER2- advanced breast cancer

Experts
Prof. Valentina Guarneri, Prof. Matteo Lambertini, Prof. Federico Rojo
  • download Downloadable
    Resources
  • clock 6 MIN
  • calendar Mar 2024

Educational programme supported by an Independent Medical Education grant from Menarini Stemline.
Podcast
Oncology 
mCRC: Optimising patient outcomes with late-line treatment

Maximising outcomes for patients with advanced CRC

Experts
Assoc. Prof. Gerald Prager, Dr Victor Hugo Fonseca de Jesus
Endorsed by
Digestive Cancers Europe 5th anniversary
  • download Downloadable
    Resources
  • clock 23 MIN
  • calendar Mar 2024

Educational programme supported by an Independent Medical Education grant from Bayer.
Interactive patient case
Oncology 
TRK fusion-positive lung cancer: Diagnosis and treatment

Make decisions for your patient at two key stages in their journey

Experts
Prof. Fernando López-Ríos, Prof. Mark Socinski
  • clock 60 MIN
  • calendar Mar 2024

Educational programme supported by an Independent Medical Education grant from Bayer
Lung cancer expert panel Conference update
Oncology 
ESMO 2023: Lung cancer update

Experts discuss new lung cancer data at a meeting hosted by eChinaHealth and COR2ED

  • clock 43 MIN
  • calendar Mar 2024

Educational programme supported by an Independent Medical Education grant from This educational programme is supported by an Independent Medical Education Grant from SystImmune and BeiGene Europe.